The Wisconsin Registry for Alzheimer’s Prevention: A Review of findings and current directions
Sterling C. JohnsoniD, Rebecca L. KoscikiD, Erin McMullen JonaitisiD, Lindsay R. ClarkiD, Kimberly Diggle MuelleriD, Sara Elizabeth BermaniD, Barbara B. BendliniD, Corinne D. EngelmaniD, Ozioma C. OkonkwoiD, Kirk J. HoganiD, Sanjay AsthanaiD, Cynthia M. CarlssoniD, Bruce P. HermanniD, Mark A. Sager
Abstract
The Wisconsin Registry for Alzheimers Prevention (WRAP) is a longitudinal observational cohort study enriched with persons with a parental history (PH) of probable Alzheimers Disease (AD) dementia. Since late 2001, WRAP has enrolled 1,561 people at a mean baseline age of 54. Participants return for a second visit four years after baseline and subsequent visits occur every two years. Eighty-one percent (1270) of participants remain active in the study at a current mean age of 64 and 9 years of follow-up. Serially assessed cognition, self-reported medical and lifestyle histories (e.g. diet, physical and cognitive activity, sleep, and mood), laboratory tests, genetics, and linked studies comprising molecular imaging, structural imaging and cerebrospinal fluid data, have yielded many important findings. In this cohort, PH of probable AD is associated with 46% APOE {varepsilon}4 positivity, more than twice the rate of 22% among persons without PH. Subclinical or worse cognitive decline relative to internal normative data has been observed in 17.6% of the cohort. Twenty-eight percent exhibit amyloid and/or tau positivity. Biomarker elevations, but not APOE or PH status, are associated with cognitive decline. Salutary health and lifestyle factors are associated with better cognition and brain structure, and lower AD pathophysiologic burden. Of paramount importance is establishing the amyloid and tau AD endophenotypes to which cognitive outcomes can be linked. Such data will provide new knowledge on the early temporal course of AD pathophysiology and inform the design of secondary prevention clinical trials.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 319
- FWCI
- 2.45
- Field percentile
- top 8%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Self-reported health behaviors and longitudinal cognitive performance: Results from the Wisconsin Registry for Alzheimer’s Prevention
Kimberly Diggle Mueller, Rebecca L. Koscik, … Sterling C. Johnson·PLoS ONEPeer-reviewed·Apr 23, 2020
- Modifiable risk factors moderate the relationship between amyloid and cognition in midlife
Lindsay R. Clark, Rebecca L. Koscik, … Sterling C. Johnson·bioRxiv·Jan 23, 2018
- The Temporal Relationships between White Matter Hyperintensities, Neurodegeneration, Amyloid β, and Cognition
Mahsa Dadar, Richard M. Camicioli, … Alzheimer’s Disease Neuroimaging Initiative·Alzheimer s & Dementia Diagnosis Assessment & Disease MonitoringPeer-reviewed·Jan 1, 2020
- APOE ε4 effects on hippocampal atrophy in the healthy elderly reflect future cognitive decline
Linda Zhang, Miguel Calero, … Bryan Andrew Strange·bioRxiv·Jan 7, 2022
- APOE4 status is related to differences in memory-related brain function in asymptomatic older adults: Baseline analysis of the PREVENT-AD task fMRI dataset
Sheida Rabipour, Sricharana Rajagopal, … Maria Natasha Rajah·Journal of Alzheimer s DiseasePeer-reviewed·May 26, 2020
- Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid
Lindsay R. Clark, Sara Elizabeth Berman, … Cynthia M. Carlsson·NeurologyPeer-reviewed·Mar 9, 2018